Aqsens Health Oy and Department of Urology at Helsinki University Hospital have started a research project for testing a new method for the detection of prostate cancer from urine. In the project parties will investigate the capabilities of Aqsens Heath’s E-TRF method and Machine Learning for classification of tumors and cancers. Results are compared to the full clinical analysis and parties are expecting to publish results in early 2020.
Prostate cancer is one of the most common cancers in men in the western world with over 1.3 million new diagnoses annually and deaths representing 6.6% of total male cancer mortality in 2015. Prostate cancer typically grows slowly and often causes no harm for the patient. However, even if some 50% of PSA era prostate cancers may be these over detected cancers that are unlikely to cause harm even if left untreated, some are aggressive as may metastasize and eventually cause mortality. Age is the best known risk factor for prostate cancer and due to the growth of the aging population prostate cancer incidence and prevalence will grow even further and hence becoming a big burden for healthcare systems.
Aqsens Health has worked intensively with urine samples and performed several non-clinical tests related to the human metabolism. “We understand how and why our E-TRF method can detect things that other methods cannot, and based on the work done we believe we can better classify prostate tumors to clinically insignificant and aggressive clinically significant cancers”, says Timo Teimonen the CEO of Aqsens Health Oy.
Prostate cancer, if detected early and still confined to the prostate gland is more likely to be successfully treated and PSA based prostate cancer screening has been shown to decrease prostate cancer mortality. However, new cost effective and more accurate methods are needed for the screening as the current PSA based screening causes too much harm, i.e. overdiagnosis of clinically insignificant cancers. “Non-invasive and urine based test, if able to better stratify men to high risk prostate cancer group, would significantly impact on the screening processes. I am excited to work with the Aqsens team and to see what our project will deliver, says Antti Rannikko the Professor of Urology at Helsinki University hospital.
In the project Aqsens Health will run E-TRF tests against clinically diagnosed and classified prostate cancers and compare results with industry gold standards. In parallel parties will conduct complementary tests using established scientific methods like mass spectrometry (MS) and nuclear magnetic resonance (NMR).
spectrometry for discovering causality of the findings. Aim of this research study is to find urine based indicators for the lethal prostate cancer.
Aqsens Health, Timo Teimonen (+358 40 585 3105) Professor of Urology, Antti Rannikko (+358 40 547 0208)
About Aqsens Health
Aqsens Health has developed a non-invasive screening and diagnosis method (E-TRF and Machine Learning) to analyse microbiota, urine and saliva, and very small-scale metabolic changes therein. The company’s focus is on non-invasive screening of health disorders having major impact for both individual patients and society.